UY34680A - Anticuerpos humanos anti-cd27, métodos, y usos - Google Patents

Anticuerpos humanos anti-cd27, métodos, y usos

Info

Publication number
UY34680A
UY34680A UY0001034680A UY34680A UY34680A UY 34680 A UY34680 A UY 34680A UY 0001034680 A UY0001034680 A UY 0001034680A UY 34680 A UY34680 A UY 34680A UY 34680 A UY34680 A UY 34680A
Authority
UY
Uruguay
Prior art keywords
methods
human antibodies
antibodies
human
escanear
Prior art date
Application number
UY0001034680A
Other languages
English (en)
Inventor
Chen John
Fransson Johan
Fursov Natalie
Hamel Damon
Malia Thomas
Obmolova Galina
Ort Tatiana
Rycyzyn Michael
Scully Michael
Sweet Raymond
Teplyakov Alexey
Wheeler John
Almagro Juan Carlos
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of UY34680A publication Critical patent/UY34680A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Los anticuerpos humanos immunoespecíficos para seres humanos CD27 son capaces de bloquear la unión de CD27 a su ligando CD70 y neutralizar la bioactividad de CD27 que incluye, pero sin limitarse a, señalización intracelular CD27, proliferación y activación de células T, proliferación y diferenciación de células B, formación de plasmablastos y alivio de las respuestas de anticuerpos, estimulación de células tumorales por CD70, y la producción de mediadores solubles de células T y B. Los anticuerpos son útiles para diagnosticar o tratar la actividad de enfermedades y estados asociados con la actividad de CD27.
UY0001034680A 2012-03-15 2013-03-15 Anticuerpos humanos anti-cd27, métodos, y usos UY34680A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261611332P 2012-03-15 2012-03-15

Publications (1)

Publication Number Publication Date
UY34680A true UY34680A (es) 2013-09-30

Family

ID=49157853

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034680A UY34680A (es) 2012-03-15 2013-03-15 Anticuerpos humanos anti-cd27, métodos, y usos

Country Status (28)

Country Link
US (6) US9102737B2 (es)
EP (1) EP2825200A4 (es)
JP (1) JP6487839B2 (es)
KR (1) KR102153374B1 (es)
CN (1) CN104284678B (es)
AR (1) AR090356A1 (es)
AU (1) AU2013232087B2 (es)
BR (2) BR122020002414B1 (es)
CA (1) CA2867299C (es)
CL (1) CL2014002416A1 (es)
CO (1) CO7071095A2 (es)
CR (1) CR20140415A (es)
EA (1) EA030828B1 (es)
EC (1) ECSP14018641A (es)
GT (1) GT201400193A (es)
HK (1) HK1206251A1 (es)
JO (1) JO3787B1 (es)
MX (1) MX363946B (es)
MY (1) MY175224A (es)
NZ (1) NZ629697A (es)
PE (1) PE20142242A1 (es)
PH (2) PH12014502011B1 (es)
SG (2) SG11201405437QA (es)
TW (2) TW201730214A (es)
UA (1) UA121844C2 (es)
UY (1) UY34680A (es)
WO (1) WO2013138586A1 (es)
ZA (2) ZA201407440B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103154034B (zh) 2010-04-13 2016-06-08 塞尔德克斯医疗公司 结合人cd27的抗体及其用途
PT2686347T (pt) 2011-03-16 2018-07-05 Argenx Bvba Anticorpos dirigidos contra cd70
WO2014140374A2 (en) * 2013-03-15 2014-09-18 Novo Nordisk A/S Monovalent cd27 antibodies
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
FR3025517B1 (fr) * 2014-09-10 2016-12-23 Repropharm Ligands potentialisants de la bioactivite des gonadotrophines
WO2017044752A1 (en) * 2015-09-10 2017-03-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
US10544229B2 (en) 2015-09-30 2020-01-28 Janssen Biotech, Inc. Agonistic antibodies specifically binding CD40 and methods of use
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
EP3364995B1 (en) * 2015-10-23 2021-08-04 Apogenix AG Single-chain cd27-receptor agonist proteins
US20170233480A1 (en) 2015-12-31 2017-08-17 Development Center For Biotechnology Anti-vegfr antibody and uses thereof
CN109071665B (zh) 2016-04-18 2022-11-01 塞德斯医疗公司 结合人cd40的激动性抗体及其用途
AU2017281830B2 (en) 2016-06-20 2023-04-06 Kymab Limited Anti-PD-L1 antibodies
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
EP3524624A4 (en) * 2016-09-29 2020-06-17 Jiangsu Hengrui Medicine Co., Ltd. ANTI-CD27 ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF, AND ITS MEDICAL USE
AR110424A1 (es) 2016-12-23 2019-03-27 Macrogenics Inc Moléculas de unión a adam9 y métodos de uso de las mismas
AU2018367896B2 (en) 2017-05-12 2023-06-01 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
JP2020525470A (ja) * 2017-07-03 2020-08-27 ディヴェロップメント センター フォー バイオテクノロジー 抗ｖｅｇｆｒ抗体及びその使用
WO2019037131A1 (zh) * 2017-08-25 2019-02-28 深圳市博奥康生物科技有限公司 一种cd27真核表达载体的构建及其高表达细胞株的制备
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
JP7359390B2 (ja) * 2018-02-09 2023-10-11 国立大学法人大阪大学 チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
CN111511767A (zh) * 2018-03-28 2020-08-07 江苏恒瑞医药股份有限公司 抗cd27抗体、其抗原结合片段及其医药用途
WO2019195452A1 (en) * 2018-04-04 2019-10-10 Bristol-Myers Squibb Company Anti-cd27 antibodies and uses thereof
EP3774898A4 (en) * 2018-04-13 2022-01-26 Dingfu Biotarget Co., Ltd. ANTI-CD27 ANTIBODIES AND THEIR USE
KR20210011919A (ko) 2018-04-17 2021-02-02 셀덱스 쎄라퓨틱스, 인크. 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
BR112020022879A2 (pt) 2018-05-11 2021-02-23 Crispr Therapeutics Ag métodos e composições para tratamento de câncer
US20210251994A1 (en) 2018-06-15 2021-08-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
UY38511A (es) 2018-12-18 2020-07-31 Argenx Bvba Terapia de combinación cd70
US20220144961A1 (en) * 2019-03-11 2022-05-12 Xyence Therapeutics, Inc. Cd27-binding antibodies and uses thereof
US20220249558A1 (en) 2019-04-30 2022-08-11 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
CA3140914A1 (en) 2019-05-24 2020-12-03 Elixiron Immunotherapeutics (hong Kong) Limited Anti-csf1r antibodies, il10 fusion proteins, and uses thereof
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
CN112646029B (zh) * 2020-12-30 2022-07-29 深圳清华大学研究院 成熟脑源性神经营养因子的抗体及其应用和诊断试剂盒
AU2022246895A1 (en) 2021-03-31 2023-10-19 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CN113444178B (zh) * 2021-06-17 2022-12-02 南京蓝盾生物科技有限公司 抗cd70内化的抗体、抗体偶联物及其应用
EP4363059A1 (en) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218525B1 (en) 1988-02-25 2001-04-17 The General Hospital Corporation Nucleic acid encoding CD28
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
US7148061B2 (en) 2000-02-11 2006-12-12 The United States Of America As Represented By The Department Of Health And Human Services Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
US6982361B1 (en) 2000-02-25 2006-01-03 The Regents Of The University Of California Method of screening a compound for anxiolytic activity in an Apolipoprotein e knockout animal
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
EP1436329A4 (en) 2001-09-20 2005-04-27 Alexion Pharma Inc ANTI-PDGF ANTIBODIES AND METHODS FOR PRODUCING FOCUSED ANTIBODIES
AU2003210266A1 (en) 2002-02-14 2003-09-04 Bioinvent International Ab Treatment, diagnosis and imaging of disease
EP1594893A2 (en) 2003-02-14 2005-11-16 Sagres Discovery, Inc. Therapeutic targets in cancer
US20090041783A1 (en) 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
WO2006130458A2 (en) 2005-06-02 2006-12-07 Astrazeneca Ab Antibodies directed to cd20 and uses thereof
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
EP2090320A1 (en) 2008-02-15 2009-08-19 Helmholtz-Zentrum für Infektionsforschung GmbH Ligands of the Natural Killer (NK) cell surface marker CD27 and therapeutic uses thereof
CN102007147B (zh) * 2008-06-30 2014-11-05 协和发酵麒麟株式会社 抗cd27抗体
ES2705015T3 (es) * 2009-12-29 2019-03-21 Kyowa Hakko Kirin Co Ltd Anticuerpo anti-CD27
CN103154034B (zh) * 2010-04-13 2016-06-08 塞尔德克斯医疗公司 结合人cd27的抗体及其用途
AU2011275749C1 (en) * 2010-07-09 2015-09-17 Aduro Biotech Holdings, Europe B.V. Agonistic antibody to CD27

Also Published As

Publication number Publication date
MY175224A (en) 2020-06-16
KR102153374B1 (ko) 2020-09-10
CL2014002416A1 (es) 2015-01-16
US20170320957A1 (en) 2017-11-09
ZA201500887B (en) 2016-01-27
PH12014502011A1 (en) 2014-11-24
SG10201710574UA (en) 2018-02-27
JO3787B1 (ar) 2021-01-31
JP6487839B2 (ja) 2019-03-20
MX2014011100A (es) 2014-12-05
GT201400193A (es) 2017-06-14
KR20140133940A (ko) 2014-11-20
JP2015511965A (ja) 2015-04-23
US9683046B2 (en) 2017-06-20
SG11201405437QA (en) 2014-10-30
CA2867299A1 (en) 2013-09-19
AU2013232087A1 (en) 2014-09-25
UA121844C2 (uk) 2020-08-10
PE20142242A1 (es) 2015-01-08
BR112014022812A2 (pt) 2017-07-18
EA201491700A1 (ru) 2015-02-27
CN104284678B (zh) 2018-04-24
EP2825200A1 (en) 2015-01-21
TWI576354B (zh) 2017-04-01
ECSP14018641A (es) 2018-10-31
US20150299330A1 (en) 2015-10-22
MX363946B (es) 2019-04-09
TW201345922A (zh) 2013-11-16
US11732050B2 (en) 2023-08-22
CA2867299C (en) 2019-08-27
US20200277393A1 (en) 2020-09-03
US9102737B2 (en) 2015-08-11
HK1206251A1 (en) 2016-01-08
BR122020002414B1 (pt) 2022-03-03
US10689453B2 (en) 2020-06-23
EP2825200A4 (en) 2015-08-26
CO7071095A2 (es) 2014-09-30
PH12017501908A1 (en) 2018-10-01
AR090356A1 (es) 2014-11-05
ZA201407440B (en) 2016-07-27
US20190248910A1 (en) 2019-08-15
CN104284678A (zh) 2015-01-14
PH12014502011B1 (en) 2014-11-24
US20240141055A1 (en) 2024-05-02
CR20140415A (es) 2014-11-18
WO2013138586A1 (en) 2013-09-19
US20130243795A1 (en) 2013-09-19
EA030828B1 (ru) 2018-10-31
AU2013232087B2 (en) 2018-02-08
TW201730214A (zh) 2017-09-01
US10301392B2 (en) 2019-05-28
NZ629697A (en) 2017-01-27
PH12017501908B1 (en) 2018-10-01

Similar Documents

Publication Publication Date Title
UY34680A (es) Anticuerpos humanos anti-cd27, métodos, y usos
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
UY34876A (es) Anticuerpos anti-egfr y usos de los mismos
BR112015014063A2 (pt) anticorpos anti-b7-h4 humano e seus usos.
UY34721A (es) Anticuerpos anti-hla-b*27 y usos de éstos.
CL2016000251A1 (es) Anticuerpos anti-activina y usos de los mismos
CL2015001924A1 (es) Anticuerpos anti-pdgfr-beta y usos relacionados.
CL2015001321A1 (es) Anticuerpos anti-ceacam5 y usos de éstos
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
BR112015006198A2 (pt) conjunto de cadeira
CL2014002342A1 (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma.
DK3083688T3 (da) Humane anti-cd40 humane antistoffer
CO6940383A2 (es) Anticuerpos anti-erbb3 y usos de los mismos
DK2935326T3 (da) Humane anti-tau-antistoffer
BR112015001459A2 (pt) anticorpos anti-kit e usos dos mesmos.
CO7020877A2 (es) Anticuerpos anti-asic1 y usos de los mismos
CL2015001266A1 (es) Anticuerpos de antihemaglutinina y métodos de uso.
CL2015003496A1 (es) Anticuerpos teicoicos anti-pared y conjugados.
BR112015004817A2 (pt) bioconjugados compreendendo antígenos modificados e seus usos
UY34271A (es) Anticuerpos anti-tie2 y usos de los mismos
CO6940376A2 (es) Anticuerpos anti-psgl-1 y usos de los mismos
BR112015007217A2 (pt) compostos e usos do composto
BR112015003032A2 (pt) anticorpos anti-jagged e métodos de utilização'.
HK1219961A1 (zh) 人抗α型干擾素抗體
UY34829A (es) Nueva dosificación y formulación

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20230529